Ipilimumab (Yervoy) and the TGN1412 catastrophe

scientific article published on 07 July 2011

Ipilimumab (Yervoy) and the TGN1412 catastrophe is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1016/J.IMBIO.2011.07.005
P698PubMed publication ID21821307

P2093author name stringRalph W Moss
Jitendra N Mehrishi
Tibor Bakacs
P433issue6
P921main subjectipilimumabQ2459042
P304page(s)583-589
P577publication date2011-07-07
P1433published inImmunobiologyQ15754985
P1476titleIpilimumab (Yervoy) and the TGN1412 catastrophe
P478volume217

Reverse relations

cites work (P2860)
Q37064737A pharmacologic perspective on newly emerging T-cell manipulation technologies
Q39316966An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomas
Q39037052Antibiotic-dependent expression of early transcription factor subunits leads to stringent control of vaccinia virus replication
Q37743471Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer
Q26740520CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas
Q37675090Chemical Tools To Monitor and Manipulate Adaptive Immune Responses
Q38523302Evolving Concepts: Immunity in Oncology from Targets to Treatments
Q35090797Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists
Q64072367MiStImm: an agent-based simulation tool to study the self-nonself discrimination of the adaptive immune response
Q88678430Obesity as an immune-modifying factor in cancer immunotherapy
Q34618599Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients
Q90172521Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
Q36687229Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study
Q92144029The pharmacology and therapeutic applications of monoclonal antibodies
Q27014693Update on the challenges and recent advances in cancer immunotherapy

Search more.